One of our educational exhibits about the most exciting future developments in advanced prostate cancer imaging has scooped a major accolade at one of the world’s biggest medical conferences.

back to all news
Pierre du Bois
10 January, 2019

One of our educational exhibits about the most exciting future developments in advanced prostate cancer imaging has scooped a major accolade at one of the world’s biggest medical conferences.
 
Dr Amish Lakhani, Consultant Oncological and Genitourinary Radiologist and Lead for Training at Paul Strickland Scanner Centre, led on production of an educational exhibit titled Next Generation Imaging in Advanced Prostate Cancer: An Overview. It was awarded a prestigious ‘Magna Cum Laude’ prize at the Radiological Society of North America (RSNA) Annual Meeting in Chicago last December, which was attended by more than 50,000 radiologists, oncologists and associated professionals. The Magna Cum Laude award is the highest honour for an educational exhibit at RSNA and went to only a few exhibits from amongst over 2,000 entries.
 
Dr Lakhani credited trainee Dr Neeral Patel (from Imperial College Healthcare NHS Trust), who he supervises, as well as his colleagues at Paul Strickland Scanner Centre: Professor Anwar Padhani, Dr Wai-Lup Wong, Dr Kathryn Wallitt, Dr Andrew Gogbashian and Dr Heminder Sokhi.
 
The educational exhibit demonstrated:
•      Next generation imaging with whole body MRI and PSMA PET-CT can detect soft tissue and bone metastases with higher sensitivity than conventional imaging tools
•      Early detection of metastases and therapy resistance with advanced imaging techniques can have therapy implications
•      Next generation imaging solutions are better at assessing therapy response than conventional imaging methods, and therefore more accurate therapy benefit assessments (including heterogeneity) are possible. This could aid in the rational development and clinical use of targeted therapies
•      Pearls and pitfalls in interpretation of next generation imaging techniques in the assessment of advanced prostate cancer

categories
2019
popular articles